Who Paid My Doc Search
Menu
Organisation paid for research Program year 2020 Source: CMS Open Payments

Summit Cancer Center

Neither a doctor nor a teaching hospital

Research payments

$556,590

24 payments

Through program year 2020, Summit Cancer Center is reported as receiving $556,590 in research payments, across 24 payments.

By program year

2 rows
Year Kind Amount Payments
2020 Research $393,121 16
2019 Research $163,469 8

Breakdown

Who paid Research payments · program years 2019–2020
  1. Acerta Pharma LLC $361,805 11 payments
  2. AstraZeneca UK Limited $143,817 4 payments
  3. AbbVie, Inc. $31,440 5 payments
  4. AstraZeneca Pharmaceuticals LP $14,352 2 payments
  5. Celgene Corporation $5,176 2 payments
Studies the money was for Research payments · program years 2019–2020
  1. A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia $146,020 2 payments
  2. A Randomized, Multicentre, Open-Label, Phase 3 Study to Compare Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator Choice of Chemoimmunotherapy in Subjects with Previously Untreated CLL Without del(17p) or TP53 Mutation $144,929 6 payments
  3. A Phase 1b 2 Open Label Multicentre Study Assessing the Safety Tolerability Pharmacokinetics and Preliminary Anti tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and or Metastatic Squamous Cell Carcinoma of the Head and Neck $84,552 1 payment
  4. Part 1 FL An Open label Phase 1b Study of ACP196 Alone or in Combination with Rituximab in Subjects with Follicular Lymphoma Part 2 MZL An Open label Phase 1b or 2 Study of Acalabrutinib Alone or in Combination with Rituximab in Subjects with Indolent Bcell Non Hodgkin Lymphoma $63,895 2 payments
  5. An Open Label Multi Centre Safety Study of Fixed Dose Durvalumab plus Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies STRONG $59,264 3 payments
  6. M16-289 $17,983 3 payments
  7. To assess the efficacy and safety of AZD9291 versus Placebo in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB IIIA non small cell lung carcinoma following complete tumour resection with or without adjuvant chemotherapy $14,352 2 payments
  8. M16-298 $9,997 1 payment
  9. A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy $6,961 1 payment
  10. A Phase 3, Randomized, Blinded, Placebo-Controlled Study of Tislelizumab (Bgb-A317) Plus Chemoradiotherapy Followed By Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-Small Cell Lung Cancer $5,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2020

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record